Details

Autor(en) / Beteiligte

• Rediti, Mattia
• Fernandez-Martinez, Aranzazu
• Venet, David
• Rothé, Françoise
• Hoadley, Katherine A
• Parker, Joel S
• Singh, Baljit
• Campbell, Jordan D
• Ballman, Karla V
• Hillman, David W
• Winer, Eric P
• El-Abed, Sarra
• Piccart, Martine
• Di Cosimo, Serena
• Symmans, William Fraser
• Krop, Ian E
• Salgado, Roberto
• Loi, Sherene
• Pusztai, Lajos
• Perou, Charles M
• Carey, Lisa A
• Sotiriou, Christos

Titel

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Ist Teil von

• Nature communications, 2023-11, Vol.14 (1), p.7053-7053, Article 7053

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity of B and T cell receptor (BCR and TCR) repertoires in the context of two phase III trials, NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women with HER2-positive breast cancer. BCR features, particularly the number of reads and clones, evenness and Gini index, are heterogeneous according to hormone receptor status and PAM50 subtypes. Moreover, BCR measures describing clonal expansion, namely evenness and Gini index, are independent prognostic factors. We present a model developed in NeoALTTO and validated in CALGB 40601 that can predict event-free survival (EFS) by integrating hormone receptor and clinical nodal status, breast pathological complete response (pCR), stromal tumor-infiltrating lymphocyte levels (%) and BCR repertoire evenness. A prognostic score derived from the model and including those variables, HER2-EveNT, allows the identification of patients with 5-year EFS > 90%, and, in those not achieving pCR, of a subgroup of immune-enriched tumors with an excellent outcome despite residual disease.